TK1 Antibodies

Thymidine kinase, cytosolic (TK1)

Gene Information

Human
Gene Name:	TK1
Uniprot:	P04183
Entrez:	7083

Family

Belongs to:
thymidine kinase family

Alternative Names

EC 2.7.1.21; thymidine kinase 1 soluble isoform; Thymidine Kinase 1; thymidine kinase 1, soluble; thymidine kinase, cytosolic; thymidine kinase-1; TK1; TK2

Molecular Weight

Mass (kDA):
25.469 kDA

Genomic Context

Human
Location:	17q25.3
Sequence:	17; NC_000017.11 (78174079..78187204, complement)

Subcellular Localizations

Cytoplasm.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Leukemia
• Lymphoma
• Malignant Paraganglionic Neoplasm
• Mammary Neoplasms
• Malignant Neoplasm Of Breast
• Lymphoid Leukemia
• Chronic Lymphocytic Leukemia
• Lung Neoplasms
• Hiv Infections

• Hyperplasia
• Tissue Adhesions
• Neoplasm Metastasis
• Mitochondrial Damage
• Malignant Neoplasm Of Lung
• Leukemia L5178
• Adenocarcinoma

Pathways

• Cell Proliferation
• Cell Cycle
• S Phase
• Dna Replication
• Cell Death
• Mitosis
• Localization
• Dna Repair
• Transport
• Cell Adhesion
• Cell Cycle Arrest
• Proteolysis
• Translation

• G1 Phase
• Metaphase
• Nucleotide Salvage
• Cell Growth
• Mitochondrial Depolarization
• Cell Division
• Gene Conversion

PTMs

• Phosphorylation
• Deamination
• Acetylation

• Dephosphorylation
• Ubiquitination
• Biotinylation

• Iodination

Research Areas

• DNA Repair
• DNA replication, Transcription, Translation and Splicing
• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TK1

Best Uses Of The TK1 Marker In Cancer Diagnosis

TK1 is a tumor biomarker closely linked to the cell growth stage. In this article, we'll learn why this biomarker has great potential in cancer diagnosis, and how it can improve patient outcomes. In this article, we'll also discuss how TK1 can be used to identify TB. After all, there's more to TB than just the tumor itself.

TK1 is a tumor biomarker

The use of TK1 in the diagnosis and monitoring of lung cancer has a variety of applications. Its high concentration in the blood serum may improve diagnosis for lung squamous cell carcinoma and adenocarcinoma. It may also help with the diagnosis of small cell lung cancer. TK1 has been studied using biochemical techniques, but the value of the test is still in its early stages.

TK1 is a highly variable protein in the blood. It is almost undetectable in normal serum, but significantly increases in the bloodstream of patients with malignant tumors. The level of serum TK1 varies with tumor type, stage, and growth rate. The presence of a treatment can increase or decrease the concentration of serum TK1. The majority of studies have looked at the diagnostic accuracy of TK1 in different types of cancer and tumor types. The most widely used method for TK1 testing is the radioenzymatic assay. However, the low level of radioactivity in this method has limited its acceptance in clinical practice.

The TK1 tumor biomarker has moderate specificity and sensitivity and can be combined with other tumor markers to enhance the diagnosis of the disease. However, the results of this meta-analysis are inconsistent with those of other studies. This may be due to the small number of studies, although the authors point out that it is still early to integrate TK1 as a tumor biomarker in risk calculators.

Serum TK1 levels are useful in screening programs. Moreover, the commercial serum TK1 kit can detect pre-malignant tumors. It has been used in over 450,000 participants in health screenings. Results of these health screenings have revealed 45,682 cases of STK1p. Furthermore, TK1 expression was determined in 6,124 cancer patients and 15 types of malignancies.

Furthermore, it has also been used to detect malignancies and physiological conditions associated with increased risk for cancer. Acute exposure to HBV, obesity, and HBV infection, are known to increase STK1p. Moreover, the elevated levels of STK1p may indicate a 3 to five-fold increased risk of malignancies over the next 6 years. Although the study results are not conclusive, they do suggest the utility of STK1p as a tumor biomarker in head and neck cancer.

It is closely linked to cell growth stage

Proliferation of cells is a hallmark of cancers, and a TK1 marker is believed to be an important tumor proliferation marker. To evaluate the prognostic value of TK1 measurement in cancer, we searched PubMed, EMBASE, and Cochrane Library for relevant studies. We selected 40 studies for full text review and included fifteen for analysis. We found that TK1 was closely associated with cell growth stage.

This biomarker is able to measure the level of DNA synthesis in cells. Besides this, it is also related to cell proliferation. Nevertheless, it does not distinguish between malignant and benign cells. The study provides new insights into TK1's role in thyroid cancer progression. TK1 markers are accessible in serum. The researchers have suggested that TK1 may play a role in cell proliferation and disruption.

The TK1 gene is located on chromosome 17q23-q25. It is involved in DNA synthesis, cell cycle regulation, and DNA repair. Its expression is also associated with prognosis in bladder cancer. To date, there are no clinical studies of TK1 and bladder cancer. However, the gene's presence on the patient's tumor tissue may play a role in prognosis.

Although the role of TK1 as a tumor marker has not been systematically explored in traditional studies, it is an excellent candidate to be used alongside other markers. The level of TK1 in serum may be used to guide treatment, but a pooled analysis is needed to confirm the findings. We have found that TK1 is a reliable tumor marker, but more studies are needed to prove its efficacy.

Serum TK1 activities and immunological concentrations are elevated in several solid tumors. These elevated levels have been linked to poor surgical outcomes. Moreover, elevated serum TK1 may be a biomarker of disease progression. For these reasons, TK1 expression is a valuable biomarker for cancer research. It may also be useful in drug discovery and development. These studies are crucial in determining which cancer treatments work best.

It is a prognostic factor

TK1 is a gene that is expressed in the body. The TK1 marker has a prognostic role in Boster bio. Previously, TK1 was found to be a poor prognostic factor in Boster bio. However, more recently, a newer test that detects TK1 activity has been developed. TK1 assays have a high sensitivity and specificity and are now more widely used in early detection of cancer.

Serum STK1 activity was measured in sera from prostate cancer patients and breast cancer patients. Serum STK1 protein levels were also measured. The STK1 specific activity was significantly different from the other two serum levels. These results suggest that a high serum STK1 level may be associated with a poor prognosis. The findings are in line with the results of the previous study.

Serum TK1 activity was detected in multiple oligomeric forms. The activity was associated with high molecular weight complexes. Serum samples from additional patients demonstrated similar results. The TK1 activity was found in several molecular forms, including those that are not correlated with activity levels. Additionally, it was found that TK1 activity levels were highly correlated with the MW of TK1 protein.

TK1 protein is an important prognostic factor in prostate and breast cancer. Studies have suggested that TK1 is a highly specific marker of these tumors. Furthermore, TK1 protein assays are highly sensitive in early detection of prostate and breast cancer. Additionally, the STK1 marker is present in low and intermediate molecular complexes. This may explain the high specificity of TK1 protein assays.

It is a diagnostic tool for TB

A sputum culture is a gold-standard TB diagnostic test with high sensitivity and specificity. This test is not a cure-all, however, and may show false negatives. It also has high false-positive rates and is susceptible to BCG vaccine-related false-negatives. A blood test, known as a culture, is also used to confirm whether a patient has latent or active TB. This test measures the immune system's response to the TB bacteria.

The new test for TB, called Actiphage(r), detects more than 20 different species of mycobacteria. The assay has been successfully used to diagnose TB in exotic and wild animals. It is currently in clinical trials for human TB diagnosis. It may be useful in reducing the global disease burden by diagnosing latent TB before it has reached an advanced stage. Actiphage(r) may be a promising new way to diagnose TB and to monitor the progression of the disease.

Current TB diagnostic methods are inadequate and ineffective in high HIV prevalence areas. However, several promising new tools are in the process of development and evaluation. This article will discuss these new technologies and highlight key barriers to their widespread adoption. If you think you have a TB-related problem, don't hesitate to contact a health care provider. The more information you have about the condition of a patient, the sooner you can treat them and stop the spread of TB.

The new assay for TB is the most important advancement in TB diagnostics in over a century. Xpert offers the potential to greatly improve TB case detection in priority populations. The new test can detect MDR-TB and HIV-associated TB in as little as two hours, which will help save lives and prevent further disease transmission. It is also compatible with HIV-infection, which is a significant barrier to the diagnosis of TB.